3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Pancreatic Neoplasms
1
Melanoma
1
Low-grade Glioma
1
Glioma
1
Diffuse Intrinsic Pontine Glioma
1
Craniopharyngioma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Radiotherapy
2
Proton Therapy
2
Mental Status and Dementia Tests
2
trametinib
1
tozuleristide
1
tovorafenib
1
tocilizumab
1
dabrafenib
1
cobimetinib
1
binimetinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Vemurafenib
1
Transurethral Resection of Bladder
1
Surgical Procedures, Operative
1
Qsymia
1
Phentermine
1
Oxytocin
1
Methionine
1
Memantine
1
Medication Errors
1
Ginkgo biloba extract
1
Exenatide
1
Donepezil
1
Contrast Media
1
CKD732
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Craniopharyngioma
×
tovorafenib
×
Clear all
NCT05465174
2026-04-23
PNOC029
University of California, San Francisco
Phase 2
Recruiting
57 enrolled